TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT
试验速览
- 阶段
- 4 期
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- early neurological deterioration
研究概览
简要总结
Investigators hypothesized that the precise regulation of blood pressure based on the changes of cerebral blood flow parameters under TCD monitoring can better improve the state of cerebral blood flow, reduce the risk of early neurological deterioration and improve the prognosis of the patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older;
- •accept EVT treatment within 6 hours of symptoms onset;
- •In selected patients with AIS within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria..
- •In selected patients with AIS within 6 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria.
排除标准
- •Pre - onset mRS>2;
- •severe dementia;
- •threatening life diseases (such as malignant tumor, etc.);
- •non acute ischemic cerebrovascular disease patients undergoing selective intravascular treatment;
- •related sound window closure can not be monitoring with TCD.
研究组 & 干预措施
Guideline blood pressure control
Control blood pressure according to guidelines
干预措施: Urapidil Hydrochloride Injection (Combination Product)
Accurate blood pressure control
Implementing accurate blood pressure management under TCD monitoring
干预措施: Urapidil Hydrochloride Injection (Combination Product)
结局指标
主要结局
early neurological deterioration
时间窗: 72 hours
the incidence of 72 hours in National Institute of Health stroke scale increased more than 4 points or National Institute of Health stroke scale Ia score more than 1 points
次要结局
- prognosis of nerve function(3 months)
